Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

AWS Announces General Availability of Amazon Managed Streaming for Apache Kafka (Amazon MSK)

Published

on

Reading Time: 5 minutes

Amazon MSK provides a fully managed, highly available, secure, and
compatible service for Apache Kafka

Vonage, Secureworks, Poshmark, Nutmeg, and Compass are among
customers and partners using Amazon MSK

SEATTLE–(BUSINESS WIRE)–Today, Amazon Web Services Inc., an Amazon.com company (NASDAQ: AMZN),
announced the general availability of Amazon MSK, a fully managed
service for Apache Kafka that makes it easy for developers to build and
run highly available, secure, and scalable applications based on Apache
Kafka without having to worry about managing the underlying
infrastructure. Amazon MSK is fully compatible with Apache Kafka,
enabling customers to easily migrate their on-premises or Amazon Elastic
Cloud Compute (Amazon EC2) clusters to Amazon MSK with no code changes.
There are no commitments or upfront investment required to run Amazon
MSK, and customers only pay for the capacity they use. To get started
with Amazon MSK visit https://aws.amazon.com/msk.

Customers use Apache Kafka to capture and analyze real-time data streams
from a range of sources, including IoT devices, website clickstreams,
financial systems, and database logs. While many customers chose to
self-manage their Apache Kafka clusters, they often spend a lot of time
and expense securing, scaling, patching, and ensuring high availability
for Apache Kafka and Apache ZooKeeper clusters, which Apache Kafka
depends on for resource management. Amazon MSK gives customers all of
the attributes of Apache Kafka combined with the availability, security,
and scalability of AWS. With just a few clicks, customers can create
Apache Kafka clusters designed for high availability that span multiple
Availability Zones (AZs). Amazon MSK continuously monitors underlying
server health, automatically replacing servers when they fail and
patching servers in need of updates. Amazon MSK also runs highly
available Apache ZooKeeper nodes at no additional cost. Amazon MSK
provides multiple levels of security for Apache Kafka clusters,
including VPC network isolation, AWS Identity and Access Management
(IAM) for AWS Application Programming Interface (API) authorization,
encryption at rest, encryption in-transit, TLS based certificate
authentication, and authorization using Apache Kafka access control
lists (ACLs). Customers can easily scale out cluster storage with a few
clicks in the AWS management console to meet changes in demand. Amazon
MSK is fully compatible with Apache Kafka, allowing customers to
continue to run applications built on Apache Kafka, use Apache Kafka
compatible tools and frameworks, and take advantage of new Apache Kafka
innovations, without having to change their code.

Advertisement
Stake.com

“Customers who are running Apache Kafka have told us they want to spend
less time managing infrastructure and more time building applications
based on real-time streaming data,” said Rajesh Sheth, General Manager
of Amazon MSK, AWS. “Amazon MSK gives these customers the ability to run
Apache Kafka without having to worry about managing the underlying
hardware, and it gives them an easy way to integrate their Apache Kafka
applications with other AWS services. With Amazon MSK, customers can
stand up Apache Kafka clusters in minutes instead of weeks, so they can
spend more time focusing on the applications that impact their
businesses.”

Customers start by creating a cluster in Amazon MSK today using the AWS
Console or the AWS CLI, and Apache Kafka clients can connect to a
cluster using Apache Kafka’s open-source APIs. Amazon MSK is available
in the US East (N. Virginia), US East (Ohio), US West (Oregon), EU
(Ireland), EU (London), EU (Frankfurt), EU (Paris), Asia Pacific
(Tokyo), Asia Pacific (Singapore), and Asia Pacific (Sydney), and will
expand to additional AWS Regions in the coming year.

Vonage is a global business cloud communications leader providing
integrated communications solutions that improve how business gets done
by enhancing a company’s customer and employee experience. Vonage uses
Apache Kafka for real-time communication between various micro-services.
“By using Amazon MSK, we reduced our maintenance overhead and built a
micro-services-based platform that enables businesses to collaborate
more productively and engage their customers more effectively,” said
Venkatesh Ennala, a software engineer with Vonage. “We can now set up
new Kafka clusters more quickly and scale these clusters as our demands
increase. Amazon MSK has removed the complexity of set up and
maintenance, allowing us to focus on what’s most important – building
innovative new capabilities for our customers.”

Secureworks (NASDAQ: SCWX) is a technology-driven cybersecurity leader
that protects organizations in the digitally connected world. “When
developing and launching our security analytics application, Secureworks
chose Amazon MSK service to accelerate time to market and reduce
infrastructure and management overhead,” said Wendy Thomas, Senior Vice
President of Business and Product Strategy at Secureworks. “This allowed
us to focus on innovation and our unique differentiators, helping
protect our customers from cyber threats.”

Poshmark is a leading social commerce platform for the next generation
of retailers and shoppers. “Through technology, our mission is to build
the world’s most connected shopping experience, while empowering people
to build thriving retail businesses. Amazon MSK has made it easy to
setup, maintain and scale Kafka clusters, enabling an end-to-end data
ingestion pipeline supported by a fully-managed service,” said Mahesh
Pasupuleti, Senior Director of Data Engineering at Poshmark. “As our
demands increase, we feel confident that we will be able to scale at
ease and expand our streaming ingestion pipelines for data enrichment
and real-time machine learning, providing an enhanced experience for our
customers.”

Advertisement
Stake.com

Nutmeg is Europe’s largest digital wealth manager, helping consumers to
grow their wealth and reach their financial goals by using cost
effective technology to boost returns. Nutmeg uses Apache Kafka to
underpin their journey towards an event driven architecture. “Since
adopting Amazon MSK, we’ve been able to significantly increase the
efficiency of our teams and reduce time spent maintaining our cluster,”
said Matt Gatrell, CTO of Nutmeg. “As our data requirements and use
cases grew, we started to experience considerable overhead and
complexity in managing our Kafka clusters. Amazon MSK has allowed us to
manage our clusters with confidence, spend less time verifying the
performance of the clusters, scale with ease, and focus more time on
innovating and building exciting real-time applications.”

Compass is a real estate technology company with a powerful end-to-end
platform that supports the entire buying and selling workflow. Compass
uses Apache Kafka to provide its agents with quick access to fresh and
accurate data from hundreds of real estate data sources nationwide.
“Streaming technology is an important part of what we do as a business,
but managing streaming technology involves a lot of heavy lifting by our
software developers,” said Joseph Sirosh, CTO of Compass. “Amazon MSK
has allowed us to eliminate a lot of this heavy lifting. By using Amazon
MSK we no longer need to spend effort on ensuring data durability,
cluster availability, and scalability, and can now focus on building
applications. Amazon MSK relieves our team from the burden of operating
and maintaining Kafka and at the same time, we experience less downtime
as our clusters are fully-managed.”

About Amazon Web Services

For 13 years, Amazon Web Services has been the world’s most
comprehensive and broadly adopted cloud platform. AWS offers over 165
fully featured services for compute, storage, databases, networking,
analytics, robotics, machine learning and artificial intelligence (AI),
Internet of Things (IoT), mobile, security, hybrid, virtual and
augmented reality (VR and AR), media, and application development,
deployment, and management from 66 Availability Zones (AZs) within 21
geographic regions, spanning the U.S., Australia, Brazil, Canada, China,
France, Germany, Hong Kong Special Administrative Region, India,
Ireland, Japan, Korea, Singapore, Sweden, and the UK. Millions of
customer—including the fastest-growing startups, largest enterprises,
and leading government agencies—trust AWS to power their infrastructure,
become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.

About Amazon

Advertisement
Stake.com

Amazon is guided by four principles: customer obsession rather than
competitor focus, passion for invention, commitment to operational
excellence, and long-term thinking. Customer reviews, 1-Click shopping,
personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle
Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa
are some of the products and services pioneered by Amazon. For more
information, visit amazon.com/about and
follow @AmazonNews.

Contacts

Amazon.com, Inc.
Media Hotline, 206-266-7180
[email protected]
www.amazon.com/pr

Advertisement
Stake.com

Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market

Published

on

Continue Reading

Billion

Industrial Hemp Market Soars from $6.6 Billion to $25.7 Billion by 2034, Fueled by Sustainable Innovation

Published

on

industrial-hemp-market-soars-from-$66-billion-to-$25.7-billion-by-2034,-fueled-by-sustainable-innovation

Industrial Hemp Playing Key Role in Carbon Sequestration and Soil Remediation Aligning with Sustainable Farming Practices

ROCKVILLE, Md., June 12, 2024 /PRNewswire/ — Based on a new research report by Fact.MR, worldwide sales of Industrial Hemp Market are estimated to reach US$ 6.6 billion in 2024. By 2034, this market is anticipated to skyrocket to a staggering US$ 25.7 billion, driven by a steady CAGR of 14.5% from 2024 onward.

Demand for industrial hemp is skyrocketing as more and more industries recognize its versatile and sustainable properties. Once overlooked, this remarkable crop is now being embraced for its myriad uses across various sectors. From textiles and construction materials to biofuels and nutritional supplements, hemp’s applications are seemingly endless.

Environmentally conscious consumers are driving much of this demand, as hemp requires minimal pesticides and herbicides, making it an eco-friendly choice for sustainable farming. Its ability to sequester carbon dioxide and remediate contaminated soil further adds to its appeal. Moreover, hemp’s durability, lightweight nature, and renewable qualities make it an attractive alternative to traditional materials in manufacturing.

Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=3989

Advertisement
Stake.com

As awareness of hemp’s benefits continues to spread, industries are investing in research and development to unlock its full potential. With its multi-faceted applications and sustainable credentials, industrial hemp is poised to become a cornerstone of the green economy, meeting the growing demand for environmentally responsible products and practices.

Key Takeaways from the Market Study:

  • Based on nature, sales of organic hemp are estimated to reach a valuation of $3.2 billion in 2024.
  • The market in Mexico is evaluated to expand at a CAGR of 13.6% from 2024 to 2034.
  • Revenue from sales of industrial hemp in East Asia is projected to reach $5.9 billion by the end of 2034.
  • The South Korean market is evaluated to reach a valuation of $1.4 billion by the end of 2034.
  • North America is analyzed to hold a global market share of 24.3% by 2034.

“Use of industrial hemp in textiles, medicines, and food, coupled with global sustainability trends, is creating opportunities for suppliers. Governments worldwide are collaborating to boost global hemp distribution,” says a Fact.MR analyst.

Increasing Awareness of Therapeutic Potential of Hemp in Medical Applications

Once relegated to the fringes, industrial hemp is rapidly emerging as a sustainable wonder crop, fueling a wave of cutting-edge innovations across diverse industries. As researchers and entrepreneurs unlock its vast potential, hemp is proving to be a versatile and eco-friendly resource, paving the way for exciting new products and applications.

The automotive industry is also exploring the use of hemp fibers as a reinforcement material for lighter, stronger, and more sustainable car parts. These natural fiber composites could reduce vehicle weight, improving fuel efficiency and reducing emissions.

Advertisement
Stake.com

In the field of biotechnology, scientists are harnessing the unique properties of hemp to develop innovative products. For instance, researchers are exploring the use of hemp-derived compounds, such as cannabidiol (CBD), for their potential therapeutic applications in various medical conditions.

Japan’s Industrial Hemp Market Poised for Rapid Growth

The industrial hemp market in Japan is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2034, with the country expected to hold a 29.4% market share by the end of the period.

Increased investment in research is crucial for unlocking the full potential of industrial hemp. Research efforts may focus on improving hemp genetics for higher yield and quality, optimizing cultivation practices, and exploring innovative applications such as advanced nanomaterials or pharmaceuticals. This investment fosters innovation and establishes a foundation for the hemp industry’s long-term growth and competitiveness in an ever-evolving market.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=3989

Advertisement
Stake.com

Expanding Opportunities in the United States Industrial Hemp Market

The industrial hemp market in the United States offers abundant opportunities for stakeholders to broaden their product portfolios. Beyond traditional uses like textiles and oils, there is significant potential for hemp-based products to evolve into biodegradable polymers, eco-friendly packaging, and even biofuels. This diversification, a prominent trend in the industrial hemp market, not only targets emerging markets but also positions hemp as a versatile and sustainable resource with applications across various industries.

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the industrial hemp market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on nature (organic, conventional), product type (fiber, seeds), and end use (food & beverages, consumer textiles, personal products, industrial applications, hemp CBD, supplements, other consumer products), across seven major regions of the world (North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and MEA).

Advertisement
Stake.com

Check out More Related Studies Published by Fact.MR Research:

Hemp-Based Products Market is expected to reach $1.8 billion in 2023 and jump to a size of $16.2 billion by 2033.

Cannabis Infused Drinks Market is predicted to race ahead and end up at US$ 8.7 billion by 2032.

Ready-to-use Therapeutic Food Market to surge from $459.9M in 2024 to $800.6M by 2034, driven by 5.7% CAGR, marking substantial growth.

Specialty Fat and Oil Market will hit $85.94 billion by 2034 with a 4.6% Annual Growth Rate.

Advertisement
Stake.com

Baking Ingredient Market is set to reach $41.48 billion by 2034, Driven by 6.5% Annual Growth Rate.

Infant Milk Formula Market: From Growth Spurts to Baby Boom – Projected Surge to $22.35 Billion by 2034.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape. 

Advertisement
Stake.com

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team[email protected]
Follow Us: LinkedIn | Twitter | Blog

 

View original content:https://www.prnewswire.co.uk/news-releases/industrial-hemp-market-soars-from-6-6-billion-to-25-7-billion-by-2034–fueled-by-sustainable-innovation-302170602.html

Continue Reading

Innocan

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Published

on

innocan-pharma-announces-successful-preliminary-safety-evaluation-of-lpt-cbd-in-minipigs

HERZLIYA, Israel and CALGARY, AB, June 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan’s single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.

 

 

Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

“We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection,” commented Dr. Eyal Kalo, the R&D Director of Innocan Pharma. “With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval.”

Advertisement
Stake.com

Professor Chezy Barenholz the CSO of Innocan Pharma added, “These results are immensely gratifying and hold significant promise as they highlight the characteristics of LPT-CBD in a physiological setting similar to humans.”

The study involved administering three ascending doses of LPT-CBD via subcutaneous injection in minipigs, followed by comprehensive monitoring of pharmacokinetics and safety parameters for 28 days. Throughout the study, the minipigs demonstrated excellent drug tolerance, as evidenced by blood clinical parameters whithin normal range, healthy appetite, and normal behavior. These findings are consistent with prior safety evaluations conducted with LPT-CBD on diverse animal models including goats and dogs, affirming the drug’s favorable tolerability profile following both single and repeated use.

Grant of Restricted Share Units                                                                                                 

The Company has granted an aggregate of 290,000 restricted share units (each, an “RSU“) to consultants. Each RSU entitles the recipient to receive one common share of the Company (a “Common Share“) on vesting. A total of 150,000 RSUs vest on May 30, 2024, and 140,000 RSUs vest on September 30, 2024. The RSUs and the underlying Common Shares are subject to a statutory hold period of four months and one day expiring on October 1, 2024.

Innocan also announces that it granted 2,380,000 stock options to employees and consultants to the Company. These options have a strike price of $0.28, with various vesting periods up to 12 months. All options expire on May 30, 2029.

Advertisement
Stake.com

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected] 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Advertisement
Stake.com

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Advertisement
Stake.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-successful-preliminary-safety-evaluation-of-lpt-cbd-in-minipigs-302169232.html

Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania